Article Sidebar

PDF (Tiếng Việt)
Published: 2025-09-30
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v194i9.3681
Issue
Vol. 194 No. 9 (2025)
Section
Các bài báo
How to Cite
Khuyên, N. T., Hiệp, N. C., & Tờ, T. V. (2025). 11. Histopathological characteristics of intrahepatic cholangiocarcinoma according to the 2019 WHO classification at K Hospital. Journal of Medical Research, 194(9), 100-110. https://doi.org/10.52852/tcncyh.v194i9.3681

11. Histopathological characteristics of intrahepatic cholangiocarcinoma according to the 2019 WHO classification at K Hospital

Nguyen Thi Khuyên, Nguyen Canh Hiep, Ta Van To

Main Article Content

Abstract

This study describes the histopathological characteristics and evaluates the correlation between histological subtypes and clinical-pathological features of intrahepatic cholangiocarcinoma according to the 2019 WHO classification. We conducted a cross-sectional descriptive study on 66 patients diagnosed with and treated for ICC at K Hospital from January 2023 to February 2025. The mean age of the patients was 59.95 ± 10.76 years old, with a male-to-female ratio of 1.87:1. The mean preoperative CA19-9 level was 202.02 ± 449.78 U/mL. The mean tumor size was 5.46 ± 2.07cm. The small duct type was the most frequent (68.2%), followed by the large duct type (19.7%), the cholangiocarcinoma subtype (4.5%), and the adenosquamous subtype (7.6%). Moderately differentiated tumors accounted for 78.8%. Vascular invasion, perineural invasion, and lymph node metastasis were observed in 51.5%, 43.9%, and 30.3% of cases, respectively. Most tumors were classified as pT1-2 stage (84.8%). The large duct type ICC had significantly higher preoperative serum CA19-9 levels, vascular invasion, perineural invasion, lymph node metastasis, and tumor invasiveness than the small duct type (p < 0.05). No significant differencewas found among histological subtypes concerning HBV infection, preoperative serum AFP levels, tumor size, histological grade, or satellite nodules in the liver.

Article Details

Keywords

Intrahepatic cholangiocarcinoma, large duct, small duct

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
2. European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023; 79(1): 181-208. doi:10.1016/j.jhep.2023.03.010.
3. Paradis V, Fukayama M, Nakanuma Y. Tumors of the liver and intraheptic bile ducts. In: Digestive System Tumours. Accessed March 18, 2025. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019.
4. Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15(2): 95-111. doi:10.1038/nrclinonc.2017.157.
5. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9): 557-588. doi:10.1038/s41575-020-0310-z.
6. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK. AJCC Cancer Staging Manual. Vol 8th. Springer; 2017.
7. Ma B, Meng H, Tian Y, et al. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020; 20:318. doi:10.1186/s12885-020-06804-6.
8. Duyên NT, Hương NT. Đặc điểm giải phẫu bệnh của ung thư biểu mô đường mật trong gan theo phân loại WHO 2019 tại Bệnh viện Bạch Mai giai đoạn 2019-2022. Tạp chí Y học Việt Nam. 2022; 521(2): 45-49. doi:10.51298/vmj.v521i2.4038.
9. Spolverato G, Ejaz A, Kim Y, et al. Tumor Size Predicts Vascular Invasion and Histologic Grade Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2014; 18(7): 1284-1291. doi:10.1007/s11605-014-2533-1.
10. Kawashima J, Akabane M, Khalil M, et al. Impact of Tumor Size on the Survival Benefit of Anatomic Versus Non-Anatomic Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. Published online April 15, 2025. doi:10.1245/s10434-025-17270-4.
11. Sigel CS, Drill E, Zhou Y, et al. Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns. Am J Surg Pathol. 2018; 42(10): 1334-1345. doi:10.1097/PAS.0000000000001118.
12. Canh HN, Takahashi K, Kosaka K, Sato Y, Harada K. Classification of intrahepatic cholangiocarcinoma microenvironment based on immune cell and tumor stromal features. J Hepatol. 2019; 70(1): e372-e373. doi:10.1016/S0618-8278(19)30728-5.
13. Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 2014; 27(8): 1163-1173. doi:10.1038/modpathol.2013.241.
14. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatol Baltim Md. 2018; 68(1): 113-126. doi:10.1002/hep.29789.
15. Torbenson M, Roger Moreira RM, Lizhi Zhang LZ. Surgical Pathology of the Liver. LWW; 2018.
16. Altman AM, Kizy S, Marmor S, Huang JL, Denbo JW, Jensen EH. Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States. J Gastrointest Oncol. 2018; 9(5): 942-952. doi:10.21037/jgo.2017.11.06.
17. Spolverato G, Kim Y, Alexandrescu S, et al. Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Ann Surg Oncol. 2015; 22(7): 2218-2225. doi:10.1245/s10434-014-4223-3.